1900 Wealth Management LLC Lowers Stock Position in Johnson & Johnson $JNJ

1900 Wealth Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 5,085 shares of the company’s stock after selling 430 shares during the quarter. 1900 Wealth Management LLC’s holdings in Johnson & Johnson were worth $777,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of JNJ. Brighton Jones LLC boosted its stake in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $218,000. Signal Advisors Wealth LLC lifted its position in shares of Johnson & Johnson by 7.1% during the first quarter. Signal Advisors Wealth LLC now owns 8,531 shares of the company’s stock worth $1,415,000 after purchasing an additional 562 shares in the last quarter. Procyon Advisors LLC lifted its position in shares of Johnson & Johnson by 14.6% during the first quarter. Procyon Advisors LLC now owns 62,994 shares of the company’s stock worth $10,300,000 after purchasing an additional 8,048 shares in the last quarter. Finally, Prospect Financial Services LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $268,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $188.51 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market cap of $453.98 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company’s 50 day simple moving average is $176.18 and its 200-day simple moving average is $162.83. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.78.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JNJ. UBS Group set a $198.00 price target on shares of Johnson & Johnson in a research report on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Johnson & Johnson in a report on Saturday, September 27th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Finally, Citigroup raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $188.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.